Technical Analysis for SLRN - Acelyrin Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 3.68% | |
| Outside Day | Range Expansion | 3.68% | |
| Wide Bands | Range Expansion | 3.68% | |
| Up 3 Days in a Row | Strength | 3.68% | |
| Oversold Stochastic | Weakness | 3.68% | |
| Shooting Star Candlestick | Bearish | 9.61% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 12 hours ago |
| Rose Above 20 DMA | about 14 hours ago |
| Rose Above Previous Day's High | about 14 hours ago |
| Up 3% | about 14 hours ago |
| Up 2% | about 14 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2024
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.88 |
| 52 Week Low | 4.14 |
| Average Volume | 1,287,717 |
| 200-Day Moving Average | 10.84 |
| 50-Day Moving Average | 6.33 |
| 20-Day Moving Average | 4.71 |
| 10-Day Moving Average | 4.35 |
| Average True Range | 0.34 |
| RSI (14) | 41.18 |
| ADX | 44.05 |
| +DI | 16.28 |
| -DI | 24.11 |
| Chandelier Exit (Long, 3 ATRs) | 5.26 |
| Chandelier Exit (Short, 3 ATRs) | 5.15 |
| Upper Bollinger Bands | 5.63 |
| Lower Bollinger Band | 3.79 |
| Percent B (%b) | 0.54 |
| BandWidth | 39.21 |
| MACD Line | -0.51 |
| MACD Signal Line | -0.63 |
| MACD Histogram | 0.1161 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.36 | ||||
| Resistance 3 (R3) | 5.31 | 5.07 | 5.26 | ||
| Resistance 2 (R2) | 5.07 | 4.92 | 5.09 | 5.23 | |
| Resistance 1 (R1) | 4.93 | 4.83 | 5.00 | 4.98 | 5.20 |
| Pivot Point | 4.69 | 4.69 | 4.72 | 4.71 | 4.69 |
| Support 1 (S1) | 4.55 | 4.54 | 4.62 | 4.60 | 4.38 |
| Support 2 (S2) | 4.31 | 4.46 | 4.34 | 4.35 | |
| Support 3 (S3) | 4.17 | 4.31 | 4.32 | ||
| Support 4 (S4) | 4.22 |
